Forbes -
10 Jun 2015 19:42
Despite continued headwinds, the company exceeded its full year guidance, which it had raised after an impressive Q3. This outperformance was primarily driven by higher front-end and pharmacy sales. While a more severe flu season worked in favor of Rite Aid, it was partially offset by the launch of new generics (which being cheaper lowered the price per prescription).
Share this Article
Comment on this Article
Please to comment